In the ADAURA study, patients with completely resected stage IB–IIIA EGFR-mutant NSCLC receiving the adjuvant osimertinib showed significantly longer DFS than those receiving a placebo, and the hazard ratio (HR)(0.12; 95% CI: 0.07–0.2) of patients with stage IIIA disease remained significantly lower [11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.